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Abstract
Background: Asthma is one of the major chronic health problems in children in the Netherlands. The Pelican is a
paediatric asthma-related quality of life instrument for children with asthma from 6–11 years old, which is suitable
for clinical practice in primary and specialized care. Based on this instrument, we developed a self-management
treatment to improve asthma-related quality of life. The Pelican intervention will be investigated in different health
care settings. Results of intervention studies are often extrapolated to other health care settings than originally
investigated. Because of differences in organization, disease severity, patient characteristics and care provision
between health care settings, extrapolating research results could lead to unnecessary health costs without the
desired health care achievements. Therefore, interventions have to be investigated in different health care settings
when possible. This study is an example of an intervention study in different health care settings. In this article, we
will present the study protocol of the Pelican study in primary and specialized care.
Method/design: This study consists of two randomized controlled trials to assess the effectiveness of the Pelican
intervention in primary and specialized care. The trial in primary care is a multilevel design with 170 children with
asthma in 16 general practices. All children in one general practices are allocated to the same treatment group. The
trial in specialized care is a multicentre trial with 100 children with asthma. Children in one outpatient clinic are
randomly allocated to the intervention or usual care group. In both trials, children will visit the care provider four
times during a follow-up of nine months. This study is registered and ethically approved.
Discussion: This article describes the study protocol of the Pelican study in different health care settings. If the
Pelican intervention proves to be effective and efficient, implementation in primary and specialized care for
paediatric asthma in the Netherlands will be recommended.
Trial registration: This study is registered by clinicaltrial.gov (NCT01109745)
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Background
Asthma [1] is the most common chronic disease in
childhood in the Netherlands. Its prevalence ranges from
3% in children aged 5–9 years to 3.7% in children aged
10–14 years [2,3]. Although the prevalence is leveling off
[4], asthma remains a significant burden for the child,
family and the society at large [5]. In the Netherlands,
children with intermittent and mild asthma are usually
treated by a family physician, while patients with more
severe or uncontrolled asthma are treated by specialized
paediatric care [6]. This implies that children with
asthma treated in primary and specialized care may dif-
fer in features like disease severity and complexity, level
of symptom control, functional status and co-morbidity
[7]. Recent reports point to substantial room for im-
provement in the management of childhood asthma [8-11].
Poor adherence to therapy and inadequately treatment are
two important reasons why asthma is uncontrolled [9].
Poor adherence has been associated with discrepancies be-
tween the perceived relevance of treatment goals between
patients and their healthcare providers. Usual care for chil-
dren with asthma focuses on reducing morbidity and
mortality by maintaining optimal asthma control, while
asthmatic children want to live a normal life with as few
limitations from their asthma as possible [12]. Taking the
child’s perception into account in the management of
its asthma could result in achieving treatment goals of
patients and providers and contribute to patient centered
care. However, recent studies pointed out that input of
children and their parents into asthma management is
only taken into account by health care providers during a
minority (6 to 10%) of medical visits [13].
One of the important treatment outcomes showing a
patient’s perspective is health related quality of life
(HRQL). HRQL is a complex of all aspects of an individual’s
subjective experience that relate to health, disease, disability
and impairment, which is usually measured in phys-
ical, emotional, cognitive and social dimensions [14-17]. A
HRQL questionnaire adds significant information about
the functional impairments of a patient to clinical and
physiological characteristics. Previous studies have shown
that the most important HRQL components for children
are consequences of asthma on peer relationships, de-
pendence on medication, shortness of breath, cough, lim-
itations in activities and limitations due to tobacco
smoke exposure [18,19].
We have previously developed a child friendly web
based tool to assess asthma-related quality of life in
paediatric asthma patients, using the so-called ‘Pelican
instrument’. In this paper, we describe the rationale for,
and the designs of two randomized controlled trials
(RCTs) that are based on the implementation of the Peli-
can instrument. In these trials the effectiveness of its im-
plementation will be evaluated in both primary and
specialized care setting in the Netherlands. Both trials are
optimally adjusted in methodological design to meet the
needs of the concerned care setting. Because of the known
differences in healthcare organization and patient charac-
teristics, it is important to establish possible effects of the
treatment in both healthcare settings separately. In the
past, results from specialized care studies have often been
extrapolated into primary care, and vice versa [20,21].
Knowing that several important differences exist between
these care setting, it is likely that this might lead to inef-
fective, unnecessary or expensive health care without the
desired health achievements. Therefore, it is crucial to
evaluate such interventions in primary as well as in
specialized care.
Hypothesis
The primary hypothesis of the Pelican study is that a self
management treatment based on HRQL information
(Pelican instrument) is able to improve HRQL on the
PAQLQ-S (> 0.5 points) in children with asthma from
6–11 years old in primary and specialized care with a
proportional difference in favour of intervention relative
to usual care of 25% of children. Furthermore, it is also
hypothesized that the instrument could improve asthma
control and satisfaction with care of parents.
Research questions
The primary research question
– Is the Pelican intervention in primary and
specialized health care effective in improving HRQL
of children with asthma?
The secondary research questions
– Is the Pelican intervention in primary and
specialized health care effective in improving HRQL
of the parents of children with asthma?
– Is the Pelican intervention in primary and
specialized health care effective in improving asthma
control of children with asthma?
– Does the Pelican intervention improve patient-
doctor relationship and satisfaction with delivered
care in primary and specialized health care?
– Is the Pelican instrument able to detect and improve
psychosocial problems?
– Is the Pelican intervention user friendly in regular
medical care and cost-effective in a primary and
specialized care setting?
Methods/design
Study design
This study consists of two RCTs: one in primary care
and one in specialized care. Because the study design,
van Bragt et al. BMC Pediatrics 2012, 12:137 Page 2 of 7
http://www.biomedcentral.com/1471-2431/12/137
sample size calculation and treatment allocation differ
between the trials, these aspects are described separately.
All other aspects apply to both trials.
170 participants in primary care will be recruited from
16 general practices in the Netherlands. The primary
care study is a multicentre parallel group study with a
hierarchical or nested design. This means that all partici-
pating patients within a general practices will be allocated
to the same treatment group (usual care or intervention
group). During visits the usual care group receives care of
the GP according NHG (Dutch GP Association) guidelines
[22]. Besides usual care, the intervention group will receive
recommendations based on the Pelican outcome by a
practice nurse as well.
The most optimal study design for intervention studies
is a multilevel design to avoid contamination between
usual care and the intervention, which is applied in the
primary care trial. There are, however, not enough out-
patient clinics in the Netherlands to be able to use a
multilevel design in specialized care. This means that
specialized nurses provide care for both patients of the
intervention and those of the usual care group. 100
participants in specialized care will be recruited in 5
outpatient clinics in the Netherlands. The usual care
group receives care according to NVK (Dutch Association
of paediatric) guidelines of paediatric asthma in the
Netherlands of a care provider (e.g. paediatrician or nurse)
[23]. The intervention group receives an intervention with
the Pelican outcome by an asthma nurse complementary
to usual care.
Sample size calculation
A multilevel power calculation was performed for the
trial in primary care based on the percentage of children
with an improvement of 0.5 points on the PAQLQ in-
strument score (Δ0.5 is the minimum clinically import-
ant difference (MCID) for the PAQLQ) [14,24]. We
consider a proportional difference in favour of interven-
tion relative to usual care of 25% of children with a
MCID to be clinically relevant. Based on the assump-
tions ICC= 0.04, α= 0.05, 1-β= 0.80, 20% of usual care
group with a 0.5 points increase in PAQLQ score, and
dropout rate of 15%, a total of 170 children with asthma
needs to be included from 16 GPs.
A power calculation was performed for the trial in spe-
cialized care based on the percentage of children with an
improvement of 0.5 points on the PAQLQ instrument
score. We consider a proportional difference in favour of
intervention relative to usual care of 25% of children
with a MCID to be clinically relevant. Based on the
assumptions α= 0.05, 1-β= 0.80, 10% of usual care group
with a 0.5 points increase in PAQLQ score, and dropout
rate = 15%, a total of 100 children with asthma needs to
be included.
Selection phase
In both trials children aged 6 to 12 years with asthma diag-
nosed by a physician will be recruited. Moreover, children
must have used their asthma medication (i.e., bronchodila-
tors and / or inhaled corticosteroids) for at least six weeks
during the previous year to confirm ‘active asthma’. Exclu-
sion criteria for these studies are: 1) a comorbide condition
that significantly influences the HRQL, 2) not being able to
attend a regular school class and 3) insufficient skill of
Dutch language.
Parents of children are informed about the study by
verbal explanation and an information brochure. For
children, age-adjusted study information is provided on
the website of the study. Written informed consent of
both official caregivers will be obtained to ensure volun-
tary and anonymous participation. In accordance with
the guidelines on scientific research with underage indi-
viduals, children may be withdrawn from the study at
any time if they object [25].
Randomisation: treatment allocation
Enrolment of participants will be performed by the general
practices or outpatient clinics. Participants can be allocated
to the usual care or intervention group. In both trials, the
minimization technique will be used to allocate participants
to treatment.. Minimisation is an advanced randomisation
technique as described by Pocock [26,27]. The balance
between both groups will be kept with consideration of
prognostic factors (categorical variables) as described below
with a computer program called Minim.
In the primary care trial general practices will be
allocated balanced on the following prognostic factors:
1) number of potential participants for study within GP
(<18 or ≥18 patients with the diagnosis asthma between
6–11 years old) and 2) usual asthma care (absence of
structured asthma care, structured asthma care for adults
or structured asthma care for children).
In the specialized care trial the minimisation technique
will be used to force treatment allocation of individual
participants with consideration of the prognostic factors
age (6–8 years old and 9–11 years old) and level of
asthma control (ACQ score <1 and ACQ score ≥ 1).
Pelican instrument
The paediatric Electronic quality of Life Instrument for
Asthmatic children in the Netherlands or Pelican is a
web-based asthma-related quality of life questionnaire
that is presented as a web-based computer game. It is ef-
fortless to complete, easy to understand (questions are
read aloud) and full of attractive sounds and pictures.
While playing the game, the child answers questions
about his or her experience of asthma. Item selection for
the Pelican was based on children’s personal perspectives
that were obtained using focus groups [18]. Items are
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concrete aspects of day-to-day life with asthma what
makes them an easy starting point for treatment and are
scored in burden experience on a 5-point Likert scale
ranging from ‘no burden at all’ (0 points) to ‘very high bur-
den’ (5 points). Scores are visually supported by emoticons.
Besides overall quality of life, the instrument has the ability
to priorities issues of asthma bothering the patient most.
Intervention
The intervention is a self-management treatment based
on the patient’s reply to the Pelican questionnaire. Treat-
ment is provided by a specialized nurse with the object-
ive to improve the patient’s asthma-related quality of
life. The nurse is trained during a 2-hour meeting in this
intervention with theoretic background, video instruc-
tions and role playing exercises. Supplementary to the
training, a minimum of five evaluation moments are
included during the trial.
The child fills out the Pelican before the scheduled visit
and the outcome is forwarded to the nurse. The interven-
tion is based on the theory of behaviour change and
shared decision making [28]. The health care provider
supports the parent and child to explore their needs and
treatment goals (according SMART principles [29]) and
think about solutions for disease related problems and
challenges. Together, the parent, child and nurse work
on a treatment plan to improve disease management
resulting in better disease outcomes. The treatment plan
is a mutual agreement that is specific, acceptable and
realistic. During the next visit, the nurse will evaluate the
effectiveness of the treatment plan: why was it successful
or unsuccessful to achieve treatment goals. If not success-
ful, the care provider will explore the causes (lack of
knowledge/skills, motivational, practical or social barriers)
and evaluate whether they can be resolved.
Study parameters
The primary outcome of the study is HRQL as measured
with the PAQLQ-S (standardised activities). The Dutch
version of the PAQLQ was validated in children≥ 6 years
and has psychometric properties similar to those reported
for the original PAQLQ [30]. Also the HRQL of the main
caregiver is assessed with the PACQLQ (paediatric asthma
caregiver quality of life questionnaire) [31].
Secondary outcomes are asthma control, psychosocial
problems and satisfaction with care. Asthma control is
measured by questionnaires such as the Asthma Control
Questionnaire (ACQ) [32], the Childhood Asthma Control
Test (C-ACT) [33] and the Asthma Therapy Assessment
Questionnaire (ATAQ) [34]. Psychometric properties of all
asthma control instruments were found to be good
[32,33,35]. Lung function with reversibility (pre- en post-
FVC, pre- and post- FEV1) and Fraction of exhaled NO1
(FeNO) will be assessed according international guidelines
[36,37]. Psychosocial problems will be measured with the
Dutch version of Strengths and Difficulties Questionnaire
(SDQ) that shows good psychometric properties [24]. An
adapted version of the Patient-Doctor relationship Ques-
tionnaire (PDRQ-9) will be used to measure parent’s satis-
faction with provided care to their child by a care provider
and other patient-doctor relationship aspects [34].
Data collection
In the recruitment phase, the parents receive a question-
naire on family characteristics (e.g., socio-economic sta-
tus, family history of respiratory diseases, composition of
family, smoking habits), child asthmatic symptoms,
medication use, attitude towards asthma [35]. All partici-
pants visit the general practices or outpatient clinic four
times during a follow-up period of 9 months. The par-
ents as well as the children fill out a questionnaire at the
start and end of the study to measure HRQL, asthma
control, psychosocial problems and satisfaction with
care. During the first visit, lung function will be mea-
sured of subjects in the primary care trial. In specialized
care, both lung function and fraction exhaled NO will be
measured during the first and last visit. Next, the parents
fill out monthly calendars on asthma control, symptoms
and medication use of their child. Finally, health care
providers, parents and children will be inquired about
the satisfaction and user friendliness of implementation
of the Pelican using structured questionnaires. Since the
Pelican study is a complex intervention, data will be col-
lected for process evaluation.
Data analysis
The primary analysis is an intention-to-treat analysis,
however both explanatory and intention-to-treat ana-
lyses will be performed. The effect of the Pelican in pri-
mary care will be analysed using multi-level analyses
techniques. The effect of the Pelican in specialized care
will be assessed using multivariate regression models. A
correction for baseline value of the outcome of interest
(e.g., HRQL, asthma control) will be added to the model.
Process evaluation and cost-effectiveness analysis
The implementation of the Pelican in health care is a
complex intervention [38]. A detailed process evaluation
is crucial to evaluate what the active ingredients are and
how they are exerting their effect. Potential barriers and
facilitators of implementation are screened in every
phase of the study, starting at the completion of the Peli-
can instrument by the child at home, the use of the Peli-
can instrument during the medical visit by the health
care professional and finally the influence on asthma
specific HRQL [39].
A cost-effectiveness analysis (CEA) from a societal per-
spective will be performed and reported according to
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national and international guidelines [40,41]. The costs
included will be program costs, direct medical costs and
indirect costs measured in their natural units and trans-
formed to costs using real prices and standard reimburse-
ment of expense tariffs. An effect is defined as a relevant
change in HRQL (i.e., ΔPAQLQ ≥0.5 point) in the denom-
inator and the total of all relevant costs in the nominator.
Ethics
Ethical approval is obtained from the Medical Ethics Com-
mittee of the Arnhem-Nijmegen region in the Netherlands.
The study protocol is extensively studied by: The Dutch
Asthma Foundation, NutsOhra and Radboud University
Nijmegen Medical Centre (RUNMC). This trial is regis-
tered by clinicaltrial.gov (NCT01109745).
Discussion
Patient centred care, especially in chronic diseases, has a
growing need to implement information on health related
quality of life (HRQL) next to clinical and physiological
measures. Although several quality of life instruments for
paediatric asthma patients already exist, the Pelican instru-
ment distinguishes itself because of its applicability in
regular medical care. In this article, we presented the
methodological design of the Pelican study. Our primary
research question is whether the use of the Pelican will im-
prove the asthma-related quality of life in children with
asthma from 6–11 years old. The secondary research ques-
tions are whether the use of the Pelican intervention will
improve asthma control, satisfaction with care and HRQL
of the parent. Furthermore, it will be evaluated whether
the Pelican is able to detect and reduce psychosocial pro-
blems. The study consists of two RCTs with a follow-up of
nine months performed in primary and specialized care.
Although the study design, sample size and treatment
allocation of participants differ between both trials,
the research questions and data collection will be
identical. The trial in primary care will be a multilevel de-
sign, while participants within outpatient clinics of specia-
lized care will be randomly allocated to the usual care and
intervention group.
The Pelican study has a couple of strong characteristics.
In this study, we choose to add another HRQL instrument
to the data collection besides the Pelican instrument as an
independent HRQL measurement to answer our primary
research question. Another strong characteristic of this
study is that the intervention will be investigated in both
principal health care settings for childhood asthma, doing
justice to the differences that exist in organisation and pa-
tient characteristic between primary and specialized care.
For example, paediatric asthma patients in primary care
show lower disease severity compared to patients in specia-
lized care [7]. This could imply different levels in room for
improvement in HRQL and thus could lead to different
effect results. Performing two trials which are methodo-
logically optimised to the health care setting leads to better
validity and reliable results of treatment effect and cost ef-
fectiveness analyses. Furthermore, a detailed process evalu-
ation will be done to map barriers and facilitators of the
treatment.
However, some drawbacks must be mentioned. It is im-
possible to perform a double-blind RCT because patients
will be aware of the treatment group allocation. In
addition, being a subject in an intervention study will cause
the Hawthorne effect, easily leading to a favourable re-
sponse [42-44]. A specific limitation of the primary care
trial is the frequency of medical visits. To keep up scientific
comparability between the two trials and actively work on
a treatment plan with the patient, the frequency of four
medical visits during a period of nine months was set. This
frequency of medical visits is usual in specialized care but
doubled the frequency of visits in primary care compared
to the recommendations in national guidelines. Usual care
in the primary care study is, therefore, best described as
‘enhanced usual care’ [45]. Increasing contact time between
child and care provider may give more favourable results.
This effect is expected to be equal in both study arms in
the primary care trial. Ideally, a usual care group without
any protocol enhancements would have been added to the
RCTs. Furthermore, we choose to let the Pelican interven-
tion be performed by a practice nurse. Nurses play an in-
creasing important role in health care for chronic patients,
such as diabetes and COPD patients. Involvement of
paediatric nurses is already part of usual care in most
paediatric outpatient clinics while paediatric asthma manage-
ment in primary care is usually provided by family physi-
cians without involvement of nurses. A recent study of
Kuethe et al. (2011) suggested that the level of asthma con-
trol in children managed by an asthma nurse is not inferior
to traditional management by primary or specialized care
physicians [46]. Our choice of practice nurse involvement
was made with the eye on expected future changes in
paediatric asthma care in family practices.
A limitation in the specialized care trial is the risk on
contamination bias. The specialized nurses in outpatient
clinics provide care for patients of the intervention and
usual care group. Although nurses were instructed not
to use intervention techniques in the usual care group,
contamination bias is unavoidable. The trained nurse in
outpatient clinics might unintentionally apply training
aspects (such as shared decision-making) during treat-
ment of patients in the usual care group and may poten-
tially minimize the difference in outcomes between the
two treatment groups.
In conclusion, the aim of this study is to assess the ef-
fectiveness of the Pelican in primary and specialized care
through a self-management treatment with the aim of
improving asthma-related quality of life in children with
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asthma from 6–11 years old. If the Pelican proves to be
effective and efficient, implementation of this instrument
in usual care for paediatric asthma will be recommended.
Although the implementation of the Pelican intervention
will be evaluated in two almost equal RCTs, it was ne-
cessary to adjust the design of both trials to fit the
concerning settings. Although, different study design
characteristics lead to less comparability between the
two trials, the unique feature of this project is that we
do not need to extrapolate study outcomes to another
care settings based on numerous assumptions, as the
intervention is evaluated simultaneously in both major
care settings.
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